Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Equity Average (2016 - 2025)

Protalix BioTherapeutics has reported Equity Average over the past 16 years, most recently at $50.6 million for Q4 2025.

  • Quarterly results put Equity Average at $50.6 million for Q4 2025, up 33.7% from a year ago — trailing twelve months through Dec 2025 was $50.6 million (up 33.7% YoY), and the annual figure for FY2025 was $45.7 million, up 19.09%.
  • Equity Average for Q4 2025 was $50.6 million at Protalix BioTherapeutics, down from $51.4 million in the prior quarter.
  • Over the last five years, Equity Average for PLX hit a ceiling of $51.4 million in Q3 2025 and a floor of -$11.1 million in Q4 2022.
  • Median Equity Average over the past 5 years was $24.6 million (2023), compared with a mean of $18.9 million.
  • Biggest five-year swings in Equity Average: tumbled 627.95% in 2022 and later surged 757.76% in 2024.
  • Protalix BioTherapeutics' Equity Average stood at -$2.9 million in 2021, then tumbled by 280.46% to -$11.1 million in 2022, then skyrocketed by 424.17% to $35.9 million in 2023, then grew by 5.34% to $37.8 million in 2024, then soared by 33.7% to $50.6 million in 2025.
  • The last three reported values for Equity Average were $50.6 million (Q4 2025), $51.4 million (Q3 2025), and $47.6 million (Q2 2025) per Business Quant data.